NASDAQ:XON - Intrexon Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.69 +0.01 (+0.21 %) (As of 05/24/2019 04:00 PM ET)Previous Close$4.69Today's Range$4.60 - $4.7552-Week Range$3.95 - $19.94Volume35,035 shsAverage Volume2.40 million shsMarket Capitalization$753.98 millionP/E RatioN/ADividend YieldN/ABeta2.18 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland. Receive XON News and Ratings via Email Sign-up to receive the latest news and ratings for XON and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XON Previous Symbol CUSIPN/A CIK1356090 Webhttp://www.dna.com/ Phone301-556-9900Debt Debt-to-Equity Ratio0.76 Current Ratio3.91 Quick Ratio3.57Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$160.57 million Price / Sales4.70 Cash FlowN/A Price / Cash FlowN/A Book Value$2.08 per share Price / Book2.25Profitability EPS (Most Recent Fiscal Year)($1.37) Net Income$-509,340,000.00 Net Margins-363.14% Return on Equity-26.52% Return on Assets-15.07%Miscellaneous EmployeesN/A Outstanding Shares160,764,000Market Cap$753.98 million Next Earnings Date8/8/2019 (Estimated) OptionableOptionable Intrexon (NASDAQ:XON) Frequently Asked Questions What is Intrexon's stock symbol? Intrexon trades on the NASDAQ under the ticker symbol "XON." How were Intrexon's earnings last quarter? Intrexon Corp (NASDAQ:XON) released its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported ($0.28) earnings per share for the quarter, meeting the consensus estimate of ($0.28). The biotechnology company had revenue of $23.30 million for the quarter, compared to analyst estimates of $32.12 million. Intrexon had a negative return on equity of 26.52% and a negative net margin of 363.14%. Intrexon's revenue was down 41.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.36) earnings per share. View Intrexon's Earnings History. When is Intrexon's next earnings date? Intrexon is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Intrexon. What price target have analysts set for XON? 4 brokers have issued 12-month target prices for Intrexon's shares. Their predictions range from $7.00 to $72.00. On average, they anticipate Intrexon's share price to reach $33.50 in the next twelve months. This suggests a possible upside of 614.3% from the stock's current price. View Analyst Price Targets for Intrexon. What is the consensus analysts' recommendation for Intrexon? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intrexon in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intrexon. What are Wall Street analysts saying about Intrexon stock? Here are some recent quotes from research analysts about Intrexon stock: 1. Northland Securities analysts commented, "We believe the company will spin-off its healthcare assets as the company has undertaken a realignment to focus the company and reduce its cash burn." (5/14/2019) 2. According to Zacks Investment Research, "We are positive on Intrexon’s efforts to expand through acquisitions, exclusive channel collaborations and joint ventures. Intrexon's expanding portfolio of technologies has enabled it to develop a robust pipeline of candidates in partnership deals, targeting a broad range of diseases including cancer. Additionally, the company announced the formation of a wholly-owned subsidiary, Precigen, Inc. as part of its structural alternatives, so that it can take better decisions regarding its health business. However, the company largely depends on ECCs and license, and collaboration deals for revenues. Any unfavorable outcome from the development of these might be a major setback and hurt the company’s prospects too. Though, estimates have remained stable ahead of its Q4 earnings release, Intrexon has a positive record of earnings surprises in recent quarters." (1/26/2019) Has Intrexon been receiving favorable news coverage? Media stories about XON stock have trended negative on Friday, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Intrexon earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. Are investors shorting Intrexon? Intrexon saw a decline in short interest in the month of April. As of April 30th, there was short interest totalling 33,664,232 shares, a decline of 6.0% from the April 15th total of 35,827,689 shares. Based on an average daily trading volume, of 5,060,658 shares, the days-to-cover ratio is presently 6.7 days. Currently, 47.8% of the shares of the company are sold short. View Intrexon's Current Options Chain. Who are some of Intrexon's key competitors? Some companies that are related to Intrexon include Medpace (MEDP), Geovax Labs (GOVX), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Bioanalytical Systems (BASI), Cleveland BioLabs (CBLI), Vitality Biopharma (VBIO) and Tenax Therapeutics (TENX). What other stocks do shareholders of Intrexon own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intrexon investors own include Nordic American Tanker (NAT), ZIOPHARM Oncology (ZIOP), Hess (HES), Boeing (BA), Opko Health (OPK), Celldex Therapeutics (CLDX), Gilead Sciences (GILD), Alibaba Group (BABA), General Electric (GE) and Wells Fargo & Co (WFC). Who are Intrexon's key executives? Intrexon's management team includes the folowing people: Mr. Randal J. Kirk, Chairman & CEO (Age 65)Mr. Rick L. Sterling, Chief Financial Officer (Age 54)Mr. Donald P. Lehr, Chief Legal Officer & Corp. Sec. (Age 43)Mr. Robert F. Walsh III, Sr. VP of Energy & Fine Chemicals Platforms (Age 60)Mr. Jeffrey Thomas Perez, Sr. VP of Intellectual Property Affairs (Age 46) How do I buy shares of Intrexon? Shares of XON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Intrexon's stock price today? One share of XON stock can currently be purchased for approximately $4.69. How big of a company is Intrexon? Intrexon has a market capitalization of $753.98 million and generates $160.57 million in revenue each year. The biotechnology company earns $-509,340,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. What is Intrexon's official website? The official website for Intrexon is http://www.dna.com/. How can I contact Intrexon? Intrexon's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at 301-556-9900 or via email at [email protected] MarketBeat Community Rating for Intrexon (NASDAQ XON)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 335 (Vote Outperform)Underperform Votes: 311 (Vote Underperform)Total Votes: 646MarketBeat's community ratings are surveys of what our community members think about Intrexon and other stocks. Vote "Outperform" if you believe XON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XON will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: P/E Growth (PEG) Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.